{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:11:31Z","timestamp":1774879891344,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Styrelsen f\u00f6r Internationellt Utvecklingssamarbete","doi-asserted-by":"publisher","award":["Co-funding CSA2016S-1618"],"award-info":[{"award-number":["Co-funding CSA2016S-1618"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40264-022-01201-3","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T11:03:06Z","timestamp":1657623786000},"page":"909-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-3213","authenticated-orcid":false,"given":"Joseph","family":"Kabatende","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-3660","authenticated-orcid":false,"given":"Abbie","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mugisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazare","family":"Ntirenganya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-7376","authenticated-orcid":false,"given":"Emile","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"1201_CR1","unstructured":"World Health Organization. Schistosomiasis Fact Sheet. Geneva; World Health Organization; 2020. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/schistosomiasis. Accessed 31 Jan 2020."},{"key":"1201_CR2","unstructured":"World Health Organization. Soil-transmitted helminth infections. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/soil-transmitted-helminth-infections. Accessed 15 Jan 2022."},{"key":"1201_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens9110920","volume":"9","author":"TD Gebreyesus","year":"2020","unstructured":"Gebreyesus TD, Tadele T, Mekete K, Barry A, Gashaw H, Degefe W, et al. Prevalence, intensity, and correlates of schistosomiasis and soil-transmitted helminth infections after five rounds of preventive chemotherapy among school children in Southern Ethiopia. Pathogens. 2020;9:1\u201314.","journal-title":"Pathogens"},{"key":"1201_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens9121076","volume":"9","author":"J Kabatende","year":"2020","unstructured":"Kabatende J, Mugisha M, Ntirenganya L, Barry A, Ruberanziza E, Mbonigaba JB, et al. Prevalence, intensity, and correlates of soil-transmitted helminth infections among school children after a decade of preventive chemotherapy in Western Rwanda. Pathogens. 2020;9:1\u201320.","journal-title":"Pathogens"},{"key":"1201_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002865","volume":"8","author":"PJ Hotez","year":"2014","unstructured":"Hotez PJ, Alvarado M, Bas\u00e1\u00f1ez MG, Bolliger I, Bourne R, Boussinesq M, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8: e2865.","journal-title":"PLoS Negl Trop Dis"},{"key":"1201_CR6","unstructured":"Global Atlas of Helminth Infections. Global burden; 2018. http:\/\/www.thiswormyworld.org\/worms\/global-burden. Accessed 21 May 2022."},{"key":"1201_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1740-8709.2007.00127.x","volume":"4","author":"A Hall","year":"2008","unstructured":"Hall A, Hewitt G, Tuffrey V, De Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. Matern Child Nutr. 2008;4:118\u2013236.","journal-title":"Matern Child Nutr"},{"issue":"1","key":"1201_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005523","volume":"12","author":"N Pabalan","year":"2018","unstructured":"Pabalan N, Singian E, Tabangay L, Jarjanazi H, Boivin MJ, Ezeamama AE. Soil-transmitted helminth infection, loss of education and cognitive impairment in school-aged children: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12(1): e0005523.","journal-title":"PLoS Negl Trop Dis"},{"key":"1201_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-016-0212-z","volume":"6","author":"N Rujeni","year":"2017","unstructured":"Rujeni N, Morona D, Ruberanziza E, Mazigo HD. Schistosomiasis and soil-transmitted helminthiasis in Rwanda: an update on their epidemiology and control. Infect Dis Poverty. 2017;6:1\u201311.","journal-title":"Infect Dis Poverty"},{"key":"1201_CR10","unstructured":"World Health Organization. Eliminating soil-transmitted helminthiases as a public health problem in children. Progress report 2001\u22122010 and strategic plan 2011\u22122020; Geneva; World Health Organization; 2012. https:\/\/www.who.int\/publications\/i\/item\/9789241503129. Accessed 21 Jan 2021."},{"key":"1201_CR11","unstructured":"World Health Organization. Update on the global status of implementation of preventive chemotherapy (PC). World Health Organization; 2020. https:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/PC_Update.pdf?ua=. Accessed 26 Feb 2021."},{"key":"1201_CR12","unstructured":"World Health Organization. Guideline: preventive chemotherapy to control soil-transmitted helminths infections in at risk population groups. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2017."},{"key":"1201_CR13","unstructured":"Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN). Rwanda: 2019. https:\/\/espen.afro.who.int\/countries\/rwanda. Accessed 6 Sept 2021."},{"key":"1201_CR14","first-page":"1","volume":"18","author":"A Barry","year":"2021","unstructured":"Barry A, Olsson S, Khaemba C, Kabatende J, Dires T, Fimbo A, et al. Comparative assessment of the pharmacovigilance systems within the neglected tropical diseases programs in East Africa\u2014Ethiopia, Kenya, Rwanda, and Tanzania. Int J Environ Res Public Health. 2021;18:1\u201313.","journal-title":"Int J Environ Res Public Health"},{"key":"1201_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14050400","volume":"14","author":"OM Minzi","year":"2021","unstructured":"Minzi OM, Mnkugwe RH, Ngaimisi E, Kinung\u2019hi S, Hansson A, Pohanka A, et al. Effect of dihydroartemisinin-piperaquine on the pharmacokinetics of praziquantel for treatment of schistosoma mansoni infection. Pharmaceuticals. 2021;14:1\u201312.","journal-title":"Pharmaceuticals"},{"key":"1201_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36:75\u201381.","journal-title":"Drug Saf"},{"key":"1201_CR17","unstructured":"World Health Organization. Assuring Safety of Preventive Chemotherapy Interventions for the Control of Neglected Tropical Diseases. Geneva: World Health Organization; 2011. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/44683. Accessed 10 Jan 2021."},{"key":"1201_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-016-1958-7","volume":"10","author":"J Zwang","year":"2017","unstructured":"Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg\/kg in preschool-aged and school-aged children: a meta-analysis. Parasites Vectors. 2017;10:1\u201316.","journal-title":"Parasites Vectors"},{"key":"1201_CR19","first-page":"1","volume":"9","author":"RH Mnkugwe","year":"2020","unstructured":"Mnkugwe RH, Minzi OS, Kinung\u02b9hi SM, Kamuhabwa AA, Aklillu E. Efficacy and safety of praziquantel for treatment of schistosoma mansoni infection among school children in Tanzania. Pathogens. 2020;9:1\u201312.","journal-title":"Pathogens"},{"key":"1201_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1086\/314686","volume":"179","author":"GR Olds","year":"1999","unstructured":"Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis. 1999;179:996\u20131003.","journal-title":"J Infect Dis"},{"key":"1201_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40264-019-00898-z","volume":"43","author":"A Barry","year":"2020","unstructured":"Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, et al. Comparative assessment of the national pharmacovigilance systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Saf. 2020;43:339\u201350.","journal-title":"Drug Saf"},{"key":"1201_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15193","author":"R Kiguba","year":"2021","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2021. https:\/\/doi.org\/10.1111\/bcp.15193.","journal-title":"Br J Clin Pharmacol"},{"key":"1201_CR23","unstructured":"World Health Organization. The Safety of Medicines in Public health programmes: pharmacovigilance an essential tool. WHO Library Catalog Data; 2006:61. https:\/\/apps.who.int\/iris\/handle\/10665\/43384. Accessed 20 May 2022."},{"key":"1201_CR24","first-page":"6","volume":"9","author":"SM Njenga","year":"2014","unstructured":"Njenga SM, Ng\u2019Ang\u2019a PM, Mwanje MT, Bendera FS, Bockarie MJ. A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya. PLoS\u00a0One. 2014;9:6\u201310.","journal-title":"PLoS\u00a0One"},{"key":"1201_CR25","first-page":"1","volume":"15","author":"M Lemos","year":"2020","unstructured":"Lemos M, Pedro JM, Fan\u00e7ony C, Moura S, Brito M, Nery SV, et al. Schistosomiasis and soil-transmitted helminthiasis preventive chemotherapy: adverse events in children from 2 to 15 years in Bengo province, Angola. PLoS\u00a0One. 2020;15:1\u201313.","journal-title":"PLoS\u00a0One"},{"key":"1201_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0035-9203(03)00003-8","volume":"98","author":"G Raso","year":"2004","unstructured":"Raso G, N\u2019Goran EK, Toty A, Luginb\u00fchl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western C\u00f4te d\u2019Ivoire. Trans R Soc Trop Med Hyg. 2004;98:18\u201327.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1201_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/tpj.2011.34","volume":"12","author":"G Yimer","year":"2012","unstructured":"Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, et al. High plasma efavirenz level and CYP2B66 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 2012;12:499\u2013506.","journal-title":"Pharmacogenomics J"},{"key":"1201_CR28","first-page":"1","volume":"7","author":"S Mugusi","year":"2012","unstructured":"Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS\u00a0One. 2012;7:1\u20139.","journal-title":"PLoS\u00a0One"},{"key":"1201_CR29","unstructured":"World Health Organization. Cohort event monitoring (CEM) for safety signal detection after vaccination with COVID-19 vaccines. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/10665338400. Accessed 10 Feb 2022."},{"key":"1201_CR30","unstructured":"World Health Organization. WHO Anthroplus Software; Software for assessing Growth and Development of the World\u2019s Children and Adolescents. Department of Nutrition for Health and Development. Geneva: World Health Organization; 2009."},{"key":"1201_CR31","unstructured":"World Health Organization. Preventive chemotherapy in human helminthiasis. Geneva: World Health Organization; 2006. http:\/\/whqlibdoc.who.int\/publications\/2006\/9241547103_eng.pdf. Accessed 30 Jan 2021."},{"key":"1201_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trstmh.2004.06.006","volume":"99","author":"A Montresor","year":"2005","unstructured":"Montresor A, Odermatt P, Muth S, Iwata F, Raja\u2019a YA, Assis AM, et al. The WHO dose pole for the administration of praziquantel is also accurate in non-African populations. Trans R Soc Trop Med Hyg. 2005;99:78\u201381.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1201_CR33","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. Cancer Therapy Evaluation Program; 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 11 Oct 2021."},{"key":"1201_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S2221-1691(12)60049-5","volume":"2","author":"B Erko","year":"2012","unstructured":"Erko B, Degarege A, Tadesse K, Mathiwos A, Legesse M. Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia. Asian Pac J Trop Biomed. 2012;2:235\u20139.","journal-title":"Asian Pac J Trop Biomed"},{"key":"1201_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3947\/ic.2018.50.1.1","volume":"50","author":"S Hong","year":"2018","unstructured":"Hong S. Albendazole and praziquantel: review and safety monitoring in Korea. Infect Chemother. 2018;50:1\u201310.","journal-title":"Infect Chemother"},{"key":"1201_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.parint.2013.10.014","volume":"63","author":"F Samuel","year":"2014","unstructured":"Samuel F, Degarege A, Erko B. Efficacy and side effects of albendazole currently in use against Ascaris, Trichuris and hookworm among school children in Wondo Genet, southern Ethiopia. Parasitol Int. 2014;63:450\u20135.","journal-title":"Parasitol Int"},{"key":"1201_CR37","doi-asserted-by":"publisher","unstructured":"Sousa-Figueiredo JC, Betson M, Atuhaire A, Arinaitwe M, Navaratnam AMD, Kabatereine NB, et al. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis. 2012;6(10): e1864. https:\/\/doi.org\/10.1371\/journal.pntd.0001864.","DOI":"10.1371\/journal.pntd.0001864"},{"issue":"3","key":"1201_CR38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ph14030264","volume":"14","author":"C Khaemba","year":"2021","unstructured":"Khaemba C, Barry A, Omondi WP, Bota K, Matendechero S, Wandera C, et al. Safety and tolerability of mass diethylcarbamazine and albendazole administration for the elimination of lymphatic filariasis in Kenya: an active surveillance study. Pharmaceuticals (Basel). 2021;14(3):264.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"1201_CR39","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/ph15050594","volume":"15","author":"AM Fimbo","year":"2022","unstructured":"Fimbo AM, Minzi OM, Mmbando BP, Gurumurthy P, Kamuhabwa AAR, Aklillu E. Safety and tolerability of ivermectin and albendazole mass drug administration in lymphatic filariasis endemic communities of Tanzania: a cohort event monitoring study. Pharmaceuticals (Basel). 2022;15(5):594.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"1201_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003286","volume":"8","author":"J Zwang","year":"2014","unstructured":"Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis: a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8(11): e3286.","journal-title":"PLoS Negl Trop Dis"},{"key":"1201_CR41","doi-asserted-by":"publisher","first-page":"712084","DOI":"10.3389\/fphar.2021.712084","volume":"12","author":"RH Mnkugwe","year":"2021","unstructured":"Mnkugwe RH, Minzi O, Kinung\u2019hi S, Kamuhabwa A, Aklillu E. Effect of pharmacogenetics variations on praziquantel plasma concentrations and schistosomiasis treatment outcomes among infected school-aged children in Tanzania. Front Pharmacol. 2021;12:712084.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1201_CR42","doi-asserted-by":"publisher","first-page":"17955","DOI":"10.1038\/s41598-021-97409-x","volume":"11","author":"RH Mnkugwe","year":"2021","unstructured":"Mnkugwe RH, Ngaimisi KE, Kinung\u2019hi S, Kamuhabwa AAR, Minzi OM, Aklillu E. Optimal single sampling time-point for monitoring of praziquantel exposure in children. Sci Rep. 2021;11(1):17955.","journal-title":"Sci Rep"},{"key":"1201_CR43","first-page":"10","volume":"17","author":"DW Njomo","year":"2010","unstructured":"Njomo DW, Tomono N, Muhoho N, Mitsui Y, Josyline KC, Mwandawiro CS. The adverse effects of albendazole and praziquantel in mass drug administration by trained schoolteachers. Afr J Health Sci. 2010;17:10\u20134.","journal-title":"Afr J Health Sci"},{"key":"1201_CR44","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1016\/S2214-109X(17)30187-0","volume":"5","author":"JT Coulibaly","year":"2017","unstructured":"Coulibaly JT, Panic G, Silu\u00e9 KD, Kova\u010d J, Hattendorf J, Keiser J. Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial. Lancet Glob Health. 2017;5:e688\u201398.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"1201_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008277","volume":"14","author":"PL Olliaro","year":"2020","unstructured":"Olliaro PL, Coulibaly JT, Garba A, Halleux C, Keiser J, King CH, et al. Efficacy and safety of single 40 mg\/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: an individual participant data meta-analysis. PLoS Negl Trop Dis. 2020;14(6): e0008277.","journal-title":"PLoS Negl Trop Dis"},{"key":"1201_CR46","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.18203\/2319-2003.ijbcp20172729","volume":"6","author":"P Agrawal","year":"2017","unstructured":"Agrawal P, Srivastava B, Bhardwaj R, Gaur S. Adverse events of albendazole due to mass drug administration. Int J Basic Clin Pharmacol. 2017;6:1674\u20137.","journal-title":"Int J Basic Clin Pharmacol."},{"key":"1201_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1108\/00346650510605630","volume":"35","author":"JA Ayo","year":"2005","unstructured":"Ayo JA, Agu H, Madaki I. Food and drug interactions: its side effects. Nutr Food Sci. 2005;35:243\u201352.","journal-title":"Nutr Food Sci"},{"key":"1201_CR48","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","volume":"85","author":"ST de Vries","year":"2019","unstructured":"de Vries ST, Denig P, Ekhart C, Burgers JS, Kleefstra N, Mol PGM, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. Br J Clin Pharmacol. 2019;85:1507\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"1201_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17: 100188.","journal-title":"EClinicalMedicine."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01201-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:32:04Z","timestamp":1659961924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01201-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"6 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as part of the Pharmacovigilance Infrastructure and Postmarketing Surveillance System Capacity Building for Regional Medicine Regulatory Harmonization in East Africa (PROFORMA) project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP)\u00a02 program supported by the European Union (Grant number CSA2016S-1618) and the Swedish International Development Cooperation Agency (SIDA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Conceptualization: AB, JK, MM, LN, EB and EA. Data curation: JK, AB, MM, LN, and EA. Formal analysis: AB, JK, LN, and MM. Investigation: JK, AB, EB, MM, and EA. Methodology: AB, JK, EB, and EA. Supervision: EB, UB, and EA. Writing\u2014original draft: JK and AB. Writing\u2014review and editing: AB, JK, MM, LN, EB, UB, and EA. All authors read and approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Joseph Kabatende, Abbie Barry, Michael Mugisha, Lazare Ntirenganya, Ulf Bergman, Emile Bienvenu, and Eleni Aklillu declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Rwandan National Ethics Committee (Review Approval Notice No. 0064\/RNEC\/2019) and the National Health Research Committee of the Ministry of Health, Rwanda (NHRC\/2018\/PROT\/042).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Participant consent was documented on a written informed consent form, which was accompanied by written information for parents\/guardians, and the informed consent forms were approved by the same Ethics Committees that approved this protocol.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available upon reasonable request owing to privacy and ethical restrictions from the authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}